Parts of this study were previously presented as a poster presentation at the 71st Scientific Sessions of the American Diabetes Association, San Diego, CA, USA, 24–28 June, 2011, and at the 9th International Diabetes Federation Western Pacific Region Congress, Kyoto, Japan, November 24–27, 2012.
Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study†
Version of Record online: 14 JUL 2013
© 2013 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Diabetes, Obesity and Metabolism
Volume 15, Issue 12, pages 1136–1145, December 2013
How to Cite
Inagaki, N., Kondo, K., Yoshinari, T., Maruyama, N., Susuta, Y. and Kuki, H. (2013), Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study. Diabetes, Obesity and Metabolism, 15: 1136–1145. doi: 10.1111/dom.12149
- Issue online: 5 NOV 2013
- Version of Record online: 14 JUL 2013
- Accepted manuscript online: 19 JUN 2013 12:30PM EST
- Manuscript Accepted: 11 JUN 2013
- Manuscript Revised: 4 FEB 2013
- Manuscript Received: 18 DEC 2012
- Mitsubishi Tanabe Pharma Corporation
|dom12149-sup-0001-AppendixS1.doc||Word document||31K||Appendix S1. Eligibility criteria and the method for sample size calculation are provided in the Supporting Information.|
|dom12149-sup-0002-FigureS1.tif||TIFF image||14434K||Figure S1. HbA1c (A), FPG (B), urinary glucose/creatinine ratio (C) and body weight (D) measured at the start (except for urinary glucose/creatinine ratio and body weight) and end of the run-in period and during the 12-week treatment period. HbA1c, haemoglobin A1c; NGSP, National Glycohemoglobin Standardization Program; FPG, fasting plasma glucose; UGE, urinary glucose excretion; CRE, creatinine.|
|dom12149-sup-0003-FigureS2.tif||TIFF image||12108K||Figure S2. Plasma glucose levels measured during the meal tolerance tests performed at baseline (end of the run-in period) and at week 12 in the treatment period in the placebo (A), 50 mg (B), 100 mg (C), 200 mg (D) and 300 mg (E) canagliflozin groups. The meal was consumed at 0 min.|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.